Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain

Supportive Care in Cancer

Volumn 23, Issue 3, 2015, Pages 823-830

  Ahmedzai, Sam H ^a   Leppert, Wojciech ^b   Janecki, Marcin ^c   Pakosz, Artur ^d   Lomax, Mark ^e   Duerr, Heike ^f   Hopp, Michael ^f  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d God s Mercy Hospice   (Poland)

^e Mundipharma Research   (United Kingdom)

^f MUNDIPHARMA GMBH   (Germany)

Author keywords

Analgesia; Bowel function; Naloxone; Opioid induced constipation; Oxycodone

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; NALOXONE PLUS OXYCODONE; URIC ACID; DELAYED RELEASE FORMULATION; DRUG COMBINATION; NALOXONE; NARCOTIC ANALGESIC AGENT; OXYCODONE; TABLET;

ABDOMINAL PAIN; ADULT; AGED; ANALGESIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BOWEL FUNCTION INDEX; BRIEF PAIN INVENTORY; CANCER PAIN; CANCER PATIENT; CHRONIC PAIN; CLINICAL EVALUATION; CLINICAL FEATURE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED CANCER; DRUG RELEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEALTH STATUS; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTESTINE FUNCTION; LONG TERM CARE; LYMPHOCYTE COUNT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NUTRITIONAL DISORDER; OPEN STUDY; PAIN SEVERITY; PATIENT ASSESSMENT; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DELAYED RELEASE FORMULATION; DRUG COMBINATION; FOLLOW UP; NEOPLASM; PAIN MEASUREMENT; PROCEDURES; SEVERITY OF ILLNESS INDEX;

AGED; ANALGESICS, OPIOID; CHRONIC PAIN; CONSTIPATION; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NALOXONE; NEOPLASMS; OXYCODONE; PAIN MANAGEMENT; PAIN MEASUREMENT; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TABLETS; TREATMENT OUTCOME;

EID: 84908631547     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-014-2435-5     Document Type: Article

References (38)

1. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS (1995) When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61(2):277–284, Epub 1995/05/01
2. Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F (2012) Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 23(Suppl 7):139–154, Epub 2012/11/20
3. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18(9):1437–1449, Epub 2007/03/16
4. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ et al (2009) Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 20(8):1420–1433, Epub 2009/02/27
5. Wiffen PJ (2005) Evidence-based pain management and palliative care in issue one for 2005 of The Cochrane Library. J Pain Palliat Care Pharmacother 19(3):65–68, Epub 2005/10/13
6. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13(2):e58–e68, Epub 2012/02/04
7. Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM et al (1998) Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 2(3):239–249, Epub 2004/04/23
8. Gimbel JS, Richards P, Portenoy RK (2003) Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60(6):927–934, Epub 2003/03/26
9. Coluzzi F, Mattia C (2005) Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol 71(7–8):451–460, Epub 2005/07/14
10. Kalso E (2005) Oxycodone. J Pain Symptom Manage 29(5 Suppl):S47–S56, Epub 2005/05/24
11. Caraceni A, Pigni A, Brunelli C (2011) Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliat Med 25(5):402–409, Epub 2011/06/29
12. King SJ, Reid C, Forbes K, Hanks G (2011) A systematic review of oxycodone in the management of cancer pain. Palliat Med 25(5):454–470, Epub 2011/06/29
13. Pappagallo M (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182(5A Suppl):11S–18S, Epub 2002/01/05
14. Ballantyne JC (2007) Opioid analgesia: perspectives on right use and utility. Pain Physician 10(3):479–491, Epub 2007/05/26
15. Panchal SJ, Muller-Schwefe P, Wurzelmann JI (2007) Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 61(7):1181–1187, Epub 2007/05/10
16. Mueller-Lissner S (2010) Fixed combination of oxycodone with naloxone: a new way to prevent and treat opioid-induced constipation. Adv Ther 27(9):581–590, Epub 2010/08/18
17. Mancini I, Bruera E (1998) Constipation in advanced cancer patients. Support Care Cancer 6(4):356–364, Epub 1998/08/08
18. Kurz A, Sessler DI (2003) Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63(7):649–671, Epub 2003/03/27
19. Ahmedzai SH, Boland J. Constipation in people prescribed opioids. Clin Evid (Online). 2010;2010. Epub 2010/01/01.
20. Choi YS, Billings JA (2002) Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage 24(1):71–90, Epub 2002/08/17
21. De Schepper HU, Cremonini F, Park MI, Camilleri M (2004) Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 16(4):383–394, Epub 2004/08/13
22. Smith K, Hopp M, Mundin G, Bond S, Bailey P, Woodward J et al (2012) Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 50(5):360–367, Epub 2012/05/01
23. Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, Foley K, Houde RW, Marsh F et al (1992) Treatment of opioid-induced constipation with oral naloxone: a pilot study. Clin Pharmacol Ther 52(1):90–95, Epub 1992/07/01
24. Clemens KE, Mikus G (2010) Combined oral prolonged-release oxycodone and naloxone in opioid-induced bowel dysfunction: review of efficacy and safety data in the treatment of patients experiencing chronic pain. Expert Opin Pharmacother 11(2):297–310, Epub 2009/12/25
25. Simpson K, Leyendecker P, Hopp M, Muller-Lissner S, Lowenstein O, De Andres J et al (2008) Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 24(12):3503–3512, Epub 2008/11/27
26. Lowenstein O, Leyendecker P, Hopp M, Schutter U, Rogers PD, Uhl R et al (2009) Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 10(4):531–543, Epub 2009/02/27
27. Vondrackova D, Leyendecker P, Meissner W, Hopp M, Szombati I, Hermanns K et al (2008) Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 9(12):1144–1154, Epub 2008/08/19
28. Sandner-Kiesling A, Leyendecker P, Hopp M, Tarau L, Lejcko J, Meissner W et al (2010) Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract 64(6):763–774, Epub 2010/04/08
29. Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M (2012) A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 26(1):50–60, Epub 2011/09/23
30. Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23(2):129–138, Epub 1994/03/01
31. Rentz AM, Yu R, Muller-Lissner S, Leyendecker P (2009) Validation of the bowel function index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ 12(4):371–383, Epub 2009/11/17
32. Ueberall MA, Muller-Lissner S, Buschmann-Kramm C, Bosse B (2011) The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res 39(1):41–50, Epub 2011/06/16
33. Frank L, Kleinman L, Farup C, Taylor L, Miner P Jr (1999) Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 34(9):870–877, Epub 1999/10/16
34. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376, Epub 1993/03/03
35. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16 (3):199–208. Epub 1990/11/05.
36. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD (1987) Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse 13(3):293–308, Epub 1987/01/01
37. Raphael J, Ahmedzai S, Hester J, Urch C, Barrie J, Williams J et al (2010) Cancer pain: part 1: pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British pain society endorsed by the UK association of palliative medicine and the Royal College of General Practitioners. Pain Med 11(5):742–764, Epub 2010/06/16
38. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H et al (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19(9):2542–2554, Epub 2001/05/02